115 related articles for article (PubMed ID: 8687451)
1. Identification of a novel inhibitor (NSC 665564) of dihydroorotate dehydrogenase with a potency equivalent to brequinar.
Cleaveland ES; Zaharevitz DW; Kelley JA; Paull K; Cooney DA; Ford H
Biochem Biophys Res Commun; 1996 Jun; 223(3):654-9. PubMed ID: 8687451
[TBL] [Abstract][Full Text] [Related]
2. Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(12):666-678. PubMed ID: 30663496
[TBL] [Abstract][Full Text] [Related]
3. In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Peters GJ; Schwartsmann G; Nadal JC; Laurensse EJ; van Groeningen CJ; van der Vijgh WJ; Pinedo HM
Cancer Res; 1990 Aug; 50(15):4644-9. PubMed ID: 2164443
[TBL] [Abstract][Full Text] [Related]
4. The relation between inhibition of cell growth and of dihydroorotic acid dehydrogenase by brequinar sodium.
de Kant E; Pinedo HM; Laurensse E; Peters GJ
Cancer Lett; 1989 Jul; 46(2):123-7. PubMed ID: 2546667
[TBL] [Abstract][Full Text] [Related]
5. Differential susceptibility of dihydroorotate dehydrogenase/oxidase to Brequinar Sodium (NSC 368 390) in vitro.
Lakaschus G; Löffler M
Biochem Pharmacol; 1992 Mar; 43(5):1025-30. PubMed ID: 1313236
[TBL] [Abstract][Full Text] [Related]
6. Site of action of two novel pyrimidine biosynthesis inhibitors accurately predicted by the compare program.
Cleaveland ES; Monks A; Vaigro-Wolff A; Zaharevitz DW; Paull K; Ardalan K; Cooney DA; Ford H
Biochem Pharmacol; 1995 Mar; 49(7):947-54. PubMed ID: 7741767
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390).
Peters GJ; Sharma SL; Laurensse E; Pinedo HM
Invest New Drugs; 1987; 5(3):235-44. PubMed ID: 2822596
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
Chen SF; Perrella FW; Behrens DL; Papp LM
Cancer Res; 1992 Jul; 52(13):3521-7. PubMed ID: 1617622
[TBL] [Abstract][Full Text] [Related]
9. Retention of in vivo antipyrimidine effects of Brequinar sodium (DUP-785; NSC 368390) in murine liver, bone marrow and colon cancer.
Peters GJ; Nadal JC; Laurensse EJ; de Kant E; Pinedo HM
Biochem Pharmacol; 1990 Jan; 39(1):135-44. PubMed ID: 2153375
[TBL] [Abstract][Full Text] [Related]
10. Antipyrimidine effects of five different pyrimidine de novo synthesis inhibitors in three head and neck cancer cell lines.
Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2018; 37(6):329-339. PubMed ID: 29723133
[TBL] [Abstract][Full Text] [Related]
11. Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
McLean JE; Neidhardt EA; Grossman TH; Hedstrom L
Biochemistry; 2001 Feb; 40(7):2194-200. PubMed ID: 11329288
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Peters GJ; Kraal I; Pinedo HM
Br J Cancer; 1992 Feb; 65(2):229-33. PubMed ID: 1739622
[TBL] [Abstract][Full Text] [Related]
13. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives.
Knecht W; Löffler M
Biochem Pharmacol; 1998 Nov; 56(9):1259-64. PubMed ID: 9802339
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Knecht W; Henseling J; Löffler M
Chem Biol Interact; 2000 Jan; 124(1):61-76. PubMed ID: 10658902
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of quinoline carboxylic acids. A new class of inhibitors of dihydroorotate dehydrogenase.
Chen SF; Papp LM; Ardecky RJ; Rao GV; Hesson DP; Forbes M; Dexter DL
Biochem Pharmacol; 1990 Aug; 40(4):709-14. PubMed ID: 2386542
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of brequinar sodium (Dup-785) against human head and neck squamous cell carcinoma xenografts.
Braakhuis BJ; van Dongen GA; Peters GJ; van Walsum M; Snow GB
Cancer Lett; 1990 Feb; 49(2):133-7. PubMed ID: 2306706
[TBL] [Abstract][Full Text] [Related]
17. Brequinar derivatives and species-specific drug design for dihydroorotate dehydrogenase.
Hurt DE; Sutton AE; Clardy J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1610-5. PubMed ID: 16406782
[TBL] [Abstract][Full Text] [Related]
18. The relationship between dihydroorotic acid dehydrogenase and in vitro and in vivo cytostatic effects of brequinar sodium (DUP-785; NSC 368390).
Peters GJ; Laurensse E; de Kant E; Nadal JC; Pinedo HM
Adv Exp Med Biol; 1989; 253B():375-82. PubMed ID: 2558540
[No Abstract] [Full Text] [Related]
19. Biological activity and mode of action of some dihydroorotic and dihydroazaorotic acid derivatives.
Miersch J; Grancharov K; Krauss GJ; Spassovska N; Karamanov G; Maneva L; Mladenova J; Golovinsky E
Biomed Biochim Acta; 1987; 46(5):307-15. PubMed ID: 3663203
[TBL] [Abstract][Full Text] [Related]
20. Effects of brequinar and ciprofloxacin on de novo nucleotide biosynthesis in mouse L1210 leukemia.
Lyons SD; Christopherson RI
Biochem Int; 1990 Dec; 22(6):939-49. PubMed ID: 1965281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
